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We read with interest the recent publication by Moxon and
aulus, outlining the management of infections with Enterobacteri-
ceae producing extended-spectrum beta-lactamase (ESBL). 1 Treat-
ent options for pediatric ESBL infections often remain limited
o carbapenems. We present evidence for the successful use of
ephalosporins in the treatment of pediatric acute pyelonephritis
aused by ESBL-producing E. coli (ESBL-APN). In addition, we re-
ort for the first time successful oral treatment of ESBL-APN with
he first generation cephalosporins. 
This retrospective study was conducted at the tertiary Chil-
ren’s Hospital, Helsinki University Hospital, Finland and was
pproved by the Institutional Research Board. We used micro-
iological surveillance system and detected 136 patients aged
–18.0 years with urine cultures positive for ESBL-
nterobacteriaceae during 1.1.2007–31.12.2016. Of them, we se-
ected only children with APN into subsequent analysis ( n = 37).
e defined APN as a combination of fever, pyuria > 50 × 10 ∗6/l,
acteriuria, abnormal C-reactive protein (CRP) and no signs of
ther focus of infection. We then excluded three individuals who
ad received empirical meropenem, ciprofloxacin and piperacillin-
azobactam. The study group thus consisted of 34 patients (13
oys, 21 girls; median age 1.0 years, range 0.1–9.0 years). 
All urine samples were obtained for culture at the hospital and
ollected into BD Vacutainer® Preservative tubes (Becton Dickin-
on and Company, Franklin Lakes, New Jersey, USA). Urine samples
ere collected from either urine bags ( n = 17) or voided midstream
 n = 17), and in most children (71%, 24/34) two subsequent samples
ere obtained prior to commencement of antibacterials. Standard
rine culture was performed. E. coli was detected in urine sam-
les of all children, and one patient was co-infected with non-
SBL Klebsiella pneumonia . All blood cultures remained negative.
ntimicrobial susceptibility categorization was done by disc test-
ng (Oxoid, Cambridge, UK) according to the EUCAST methodology
nd clinical breakpoints for SIR interpretation ( www.eucast.org ). Of
he tested E. coli isolates, 100% (34/34) demonstrated susceptibility
o carbapenems and to fosfomycin (19/19), 94% (32/34) to nitro-
urantoin, 88% (29/33) to netilmycin, 64% (21/33) to tobramycin,
3% (17/27) to ciprofloxacin and 29% (10/34) to trimethoprim-
ulfamethoxazole. The ESBL production was confirmed with a com-
ination disc test according to the manufacturer (Mast Group,
ootle, UK). Abbreviations: CRP, C-reactive protein; ESBL, extended-spectrum beta-lactamase; 
SBL-APN, acute pyelonephritis caused by ESBL-producing bacteria; i/v, intravenous; 






163-4453/© 2018 The British Infection Association. Published by Elsevier Ltd. All rights rThe majority of children (79%, 27/34) presented with the first-
ime UTI and had no co-morbidities and no abnormalities on uri-
ary tract ultrasound. Others had a documented history of previ-
us UTI ( n = 4), structural abnormalities of the urinary tract ( n = 3),
idney transplants ( n = 2), and neurogenic bladder ( n = 1). 
Fifteen children (44%, 15/34) were treated as inpatients and
heir mean duration of hospitalization was 4.3 days (standard
eviation (SD) 2.71 days). Initial empiric therapy included oral
efalexin ( n = 9, 27%), intravenous (i/v) cefuroxime ( n = 12, 35%)
r parenteral ceftriaxone ( n = 13, 38%). After the data on an-
imicrobial susceptibility became available, patients were treated
ith either oral nitrofurantoin ( n = 11), carbapenems ( n = 7), oral
rimethoprim-sulfamethoxazole ( n = 5), oral ciprofloxacin ( n = 4) or
/v netilmycin ( n = 2). The therapy of five patients was not changed,
espite the microbiological resistance data. 
The majority of patients (88%, 30/34) recovered clinically while
eceiving empiric cephalosporin therapy. Clinical recovery was de-
ned as defeverscence in ≤ 48 h. Of the remaining four patients
ho defeverced within 72 h, three had their therapy switched ac-
ording to the microbiological resistance data, while one continued
o receive oral cefalexin. 
Altogether, two children (6%) experienced a recurrence caused
y ESBL- E. coli , 2 and 4 weeks after the initial ESBL-APN episode.
ne of them had received ertapenem as the definitive treatment of
he initial ESBL-APN episode (first treated empirically with i/v cef-
riaxone), while other had been treated with oral cefalexin only.
ontrol urine samples were obtained in 59% (20/34) of patients
rom three days to four weeks after the commencement of ther-
py. Of these 20 samples, 15 tested (75%) negative and five (25%)
ere positive for ESBL- E. coli . However, despite positive cultures, 2
f the 5 samples showed no pyuria and leukocyte counts were low
6–7 cells ×10 ∗6/l) in another 2 samples. Seven patients (64%, 7/11)
emonstrated microbiological recovery while still on inappropriate
herapy. 
Subgroup of children with no co-morbidities . For the 27 children
ith first-time APN and with no co-morbidities, we selected 27
ontrols with non-ESBL-APN who were matched for age, gender
nd the absence of co-morbidities. Supplementary Table 1 presents
he comparison of their clinical, laboratory and outcome data,
hile Fig. 1 demonstrates the rates of clinical and microbiologi-
al recovery in patients and controls. Ethnic background differed
ignificantly among patients and controls, as more patients of non-
innish origin had ESBL-APN ( p = 0.001). The rate of clinical recov-
ry appeared identical in both groups, which is in conjunction with
revious studies. 2 Recurrences were actually more common in the
on-ESBL-APN group (4/27 vs 1/27 in ESBL-APN group). The mean
uration of hospitalization was 3.0 days (SD 1.48 days) in patients
ith ESBL-APN ( n = 11) and 2.8 (SD 1.14 days) in those with non-
SBL-APN ( n = 10, p = 0.731). The kinetics of CRP appeared similar
n both groups (see Supplementary Fig. 1 ). eserved. 
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Fig. 1. Clinical and microbiological recovery rates in the study patients while on inappropriate empiric therapy with cephalosporins. Subgroup of patients with acute 
pyelonephritis (APN) caused by extended-spectrum beta-lactamase producing (ESBL)- E. coli and with no co-morbidities is compared to their age- and gender-matched 





















































The good response to cephalosporins in the therapy of ESBL-
E. coli APN can be partly explained by the high concentration
of cephalosporins in urine. 3 Furthermore, some children with UTI
may be able to control the infection spontaneously and recover
without proper treatment, as has been shown in some patients
with bacterial pneumonia. 4 
We acknowledge that the retrospective nature of our study
complicated the appropriate follow-up of the patients. It is possi-
ble, but unlikely, that recurrences may have been treated in other
hospitals. Further, the relatively small number of patients resulted
from the low prevalence of ESBL in Finland. Blood cultures were
negative in all our patients, thus our results should not be extrap-
olated to children with severe bacteremic ESBL-APN. In addition,
empiric therapy was changed in many patients after the micro-
biological susceptibility data became available, thus the definitive
therapy may have affected the rate of recurrences. 
In conclusion, children with APN caused by ESBL- E. coli showed
good response to suboptimal cephalosporin therapy. We do not
recommend treating ESBL-APN with cephalosporins, however, if
such patients have been cured with this therapy, further parenteral
treatment with broad-spectrum antibiotics such as carbapenems
may not be necessary. 
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p  In current times leprosy is a disease widespread especially in
he tropical and sub-tropical environments of developing coun-
ries 1 , where it still represents a relevant public health problem.
owever, in the past this disease also involved the European terri-
ory. During the 12–14th centuries, leprosy had a remarkable dif-
usion in the Western World at the time of Crusades. The large
umber of leprosaria founded almost all over Europe, and the os-
eoarchaeological cases of leprosy, are eloquent evidences of the
ell-established presence of the disease in late Medieval Europe. 2 
lthough leprosy is characterised by a low grade of infectivity,
n Medieval collective imagery its deforming impact on the body
aised terror and repugnance towards the patients affected. Lepers
ere a sort of living dead, considered unclean or morally corrupt
y Medieval society. They had to wear special clothes, to carry a
ell announcing their presence, and they were segregated in lazar
ouses outside the urban centres. 3 
Leprosy, or Hansen’s disease, is a chronic infection caused by
ycobacterium leprae , characterised by involvement of skin, mu-
ous membranes, and nerves. The disease has been classified into
 number of clinical types, the most severe of which is its lepro-
atous form, in which the immune response is poor. Transmission
ccurs through the airborne spread of nasal secretion. 
The organism has a predilection for the cooler parts of the body
nd, therefore, the most affected regions are the nose and the ex-
remities. The result is deformity of the face with resorption of
he nasal cartilage and loss of sensory perception in the fingers
nd toes. Peripheral anaesthesia can lead to the atrophy of mus-
le activity with resorption of the tubular bones of hands and feet,
hich can eventually fall off for secondary infections or involun-
ary trauma. Lesions can also affect the conjunctivae, causing ker-
titis, iridocyclitis, up to blindness. 4 
Medieval iconography is not exempt from representations of
epers which, even so, are generally very stereotyped, with the dis-
ase simply symbolised through dots spread over the body. 5 How-eprosy in the Pisan fresco “Triumph of Death”
1336–1341)  ,  ,  Abbreviations: CRP, C-reactive protein; ESBL, extended-spectrum beta-lactamase; 
SBL-APN, acute pyelonephritis caused by ESBL-producing bacteria; i/v, intravenous; 
D, standard deviation; UTI, urinary tract infections. 
 Funding: None. 
 Declarations of interest: None 
 Authorship: All authors had access to the data and played a role in writing this 
anuscript. 
fi
ver, a famous Tuscan fresco of the first half of the 14th century
ffers the first realistic representation of the disease ( Fig. 1 ). 
The “Triumph of Death” of the Monumental Cemetery of Pisa,
 pictorial masterpiece of Italian Medieval art dated back to the
ears 1336-1341, is attributed to Buonamico Buffalmacco 6 . In the
resco, which occupies a wall of 5.6 × 15 m, the author follows a
ictorial address characterised by expressionist realism. In the cen-
re of the scene Death, personified in a sort of winged demon with
at wings and sickle, and about to invest a group of wealthy young
eople on the right, totally ignores a bunch of beggars on the left
f the fresco, who invoke her as the liberation of their sorrows.
 cartouche, almost a comic, gives voice to the group of beggars,
ho thus reproach the Grim Reaper: “As prosperity has left us, oh
eath, medicine of all evil, come and give us the last supper”. 
Among the group of beggars who invoke death as extreme con-
olation to their disasters, the figure of a leper is clearly defined,
ppearing as an individual with the typical Facies leprosa . The man
hows atrophy of the nasal region where the nasal cartilage is
otally lacking, and probably blindness, since the eye is without
he pupil and seems obscured. The upper limbs, stretched towards
eath, appear as two stumps totally deprived of the hands at the
evel of the wrists. Another beggar in the group appears blind, with
is eyes covered by a bandage, and his right hand reduced to a
tump, wrapped in a rag closed by a string at the wrist. It is in
oth cases the iconographic description of a rather typical and ad-
anced stage of the pathology. 
Leprosy constitutes a sort of archetypal disease for the Medieval
orld; the leper is seen as a shameful being, struck by a disease
hat is a kind of divine curse. In the case of Pisa, we observe a di-
ascalic representation, like a figurative sermon that fits well with
he search for greater realism aimed at impressing the observer: in
he fresco the leper is the exemplar model of the sinner. 7 
The remarkable fact that distinguishes the lepers of the ceme-
ery of Pisa is, indeed, the highly realistic style of representation
or the first time so accentuated in Western art, as the result of a
robably direct observation of the disease, and not a stereotyped
guration, as Medieval art has usually been up to that time. 
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Fig. 1. “The Triumph of Death” of Buonamico Buffalmacco in the Monumetal Cemetery of Pisa (years 1336–1441). Particular of the group of beggars with two lepers [The 
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We read with great interest, the recently published meta-
nalysis by Lee et al., 1 who concluded that pentraxin-3(PTX-3) sig-
ificantly predicted disease severity and mortality in sepsis. How-
ver, we wish to raise some questions about the study. 
First, Lee et al. 1 aimed to evaluate the predictive value of PTX-3
n the population with sepsis, however, some studies 2 –4 analyzed
n the meta included patients who were not septic, the predictive
alues of PTX-3 from the non-septic population were not separated
rom the whole population, thus we were afraid that biases may
xist and make the final result inaccurate. 
Second, Lee et al. 1 claimed they searched PubMed and EMBASE
or eligible studies by using the following terms: [pentraxin-3 mor-
ality sepsis]. However, we are afraid that this search strategy may
ot be systematic or accurate, some important researches may be
issed. For example, one study 5 investigated the predictive value
f PTX-3 in the septic population and could be retrieved in the
ubmed, but it had not been incorporated into the meta-analysis
hough it should be. 
Third, some data in the meta-analysis need to be checked again
n Table 1 , the unit of following up time should be day rather than
onth. The sample size of the population with cirrhosis in Fan’s
tudy should be 156(48 + 108) rather than 277, while the sam-
le size of the population with acute kidney injury in critically
ll in Schilder’s study should be 42 rather than 13, the number of
ales in Bastrup-Birk’s study should be 139 rather than 138, and
o on. 
Fourth, in Fig. 1 of the meta, the difference in means/median
f the study by Huttunen et al. should be 41.5 rather than 38.4 as
he latter value was the difference in maximum value between the
urvivors and non-survivors. In Fig. 2 , the lower limit and upper
imit of 95% confidence interval (CI) of hazard ratio (HR) for high
TX-3 levels and risk of mortality in Kim et al.’ study should behat is the criterion of ‘high’ pentraxin-3(PTX-3) cutoff
n patients with sepsis?  Abbreviations: CRP, C-reactive protein; ESBL, extended-spectrum beta-lactamase; 
SBL-APN, acute pyelonephritis caused by ESBL-producing bacteria; i/v, intravenous; 
D, standard deviation; UTI, urinary tract infections(PTX-3), pentraxin-3; (CI), confi- 
ence interval; (HR), hazard ratio; (OR), odds ratio. 
 The work of this submission was conducted at the Emergency Department, 
uangdong Provincial Hospital of Chinese Medicine, Guangzhou, 510120, China. 2.46, 15.85) rather than (2.82, 18.17). Besides, odds ratio (OR) is
otally different from hazard ratio (HR), the authors of the meta
ay mix up the two notions (OR and HR) in the study carried by
agenaar et al. in Fig. 2 . 
Fifth, there is no clear definition and limit for “more severe sep-
is and less severe sepsis” in the meta-analysis, it can be several
ifferent com pared groups such as “severe sepsis and sepsis”, “sep-
ic shock and severe sepsis” and “septic shock and sepsis” which
an cause variable results if not specified as two specific groups.
esides, Fig. 2 lists the studies which investigate the relationship
etween ‘high’ PTX-3 and risk of mortality. Nevertheless, there are
ifferent criterion of ‘high’ PTX-3 value in different studies in the
eta-analysis, varying from 3.35 ng/ml 6 to 140 ng/ml 7 , obviously,
high’ PTX-3 concentration in one study may be deemed as ‘low’ in
thers studies, different cutoffs of ‘high’ PTX-3 should have differ-
nt predictive value for death, so we suggest the authors provide
 unified criterion for ‘high’ PTX-3 value or just indicate different
utoff of ‘high’ PTX-3 in each study. 
Sixth, systemic levels of PTX3 are well known to be influenced
y the age of the patients and underlying disease 8 , as this meta-
nalysis contains adult and pediatric studies together and infec-
ious diseases in different severity, we strongly suggest the authors
arry out subgroup analysis according to the age and the severity
f illness. 
Finally, we appreciate Lee et al. for their innovative work, but
urther rigorous validating studies are still needed. 
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Table 1 




size ( n ) 




Variables in multivariate model Ref. 
Jie (2017) ICU septic shock 112 59 20 55 28 Multivariate: no parameters provided 12 
Kim (2017) Sepsis 83 71 10 47 28 (Univariate) 13 
Caironi 
(2016) 
Severe sepsis 958 70 15 563 90 Age, sex, body mass index, reason for ICU admission, SAPS 
II and SOFA scores, pre-existing conditions (liver disease, 
chronic obstructive pulmonary disease, chronic renal 
failure, immunodeficiency, congestive or ischaemic heart 
disease), mean arterial pressure, fraction of inspired 
oxygen FiO2, diuresis, serum concentrations of lactate, 
albumin, bilirubin and creatinine, blood platelets, septic 
shock at randomization, mechanical ventilation, antibiotics 
at randomization, positive blood culture, plasma 
concentrations of presepsin and high-sensitive cardiac 




Necrotizing soft tissue 
infections 
135 61 13 84 510 Age, sex, chronic disease and Simplified acute Physiology 
Score II 
10 
Fan (2016) Cirrhosis 277 54 26 139 90 Multivariate: no parameters provided 9 
Schilder 
(2015) 
Acute kidney injury in 
septicaemia 
13 70 45 7 30 (Univariate) 17 
Elghandour 
(2015) 
Acute leukaemia in 
septicaemia 
60 39 7 28 3 (Univariate) 








Suspected infection 537 64 21 310 365 ICU stay, hypotension, use of vasopressors, acute renal 
insufficiency, disseminated intravascular coagulation, 
decreased Glasgow Coma Scale, need of mechanical 
ventilation, severe sepsis, MOF, plasma CRP levels, plasma 
procalcitonin levels, white cell count, platelet count 
19 
Lin (2013) Ventilator-associated 
pneumonia 
136 64 12 80 28 APACH II score, CPIS, SOFA score, PO2/FiO2, creatinine, 




Bacteraemia 132 62 19 70 30 Age and sex 11 
Mauri 
(2010) 
Severe sepsis and 
septic shock 




with and without 
sepsis 





26 3 8 14 3 (Univariate) 18 
Muller 
(2001) 
Critically ill (SIRS, 
sepsis, severe sepsis, 
septic shock) 
101 – – – 1 (Univariate) 16 
Fig. 1. Mean difference of PTX-3: non-survivors vs. survivors. 
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